Anti-herpesvirus Drugs and Vaccines

Edited by
June 2022
180 pages
  • ISBN978-3-0365-4037-5 (Hardback)
  • ISBN978-3-0365-4038-2 (PDF)

This book is a reprint of the Special Issue Anti-herpesvirus Drugs and Vaccines that was published in

Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare

Since the advent of the first drugs to treat herpesvirus infections, the antimicrobial community has been looking for better and more specific drugs and vaccines to both prevent and suppress these infections. The greatest active pharmaceutical ingredient that has been discovered since then is acyclovir and its derivatives, and the greatest vaccine successes against human herpesviruses have been against the varicella zoster virus. Antiherpetic drug and vaccine discovery continues to this day, an example of which being the recent clinical licensing of drugs such as letermovir and animamevir and vaccines such as Shingrix. This Special Issue takes a look at both the current antiherpetic interventions that are available today, such as the medications and vaccines that are used both prophylactically and therapeutically, and the direction that the field is headed toward in the near future. We also explore newer ideas for long-term suppression.

  • Hardback
© 2022 by the authors; CC BY-NC-ND license
Epstein–Barr virus; integrated stress response; arsenic; acyclovir; ganciclovir; cidofovir; vidarabine; foscarnet; amenamevir; docosanol; nelfinavir; HSV-1; HSV-2; herpes simplex viruses; vaccines; complement; C1q; glycoprotein D; glycoprotein B; complement-dependent cytolysis; complement-dependent neutralization; herpes simplex viruses; natural products; antiherpetic drugs; resistance; RLS-0071; PIC1; antiviral; herpes simplex type 1; acyclovir-resistance; zosteriform infection; anti-inflammatory; complement; neutrophil; wound healing; amenamevir; helicase-primase inhibitor; herpes simplex virus; varicella-zoster virus; herpes zoster; antivirals; herpes simplex virus; herpesviruses; live-attenuated vaccines; vaccines; KSHV; HHV-8; Kaposi’s sarcoma; multicentric Castleman’s disease; primary effusion lymphoma; DNA polymerase; LANA; TK (ORF21); PK (ORF36); ORF59; vFLIP; RTA; LANA; CRISPR-Cas9; cytomegalovirus; mouse cytomegalovirus; piperidine-4-carboxamides; add-on removal; herpes simplex virus type 2; nucleoside-modified mRNA; lipid nanoparticle; glycoprotein D; genital herpes vaccine; IgG ELISA; neutralizing antibodies; epitope mapping; surface plasmon resonance; guinea pig; cytomegalovirus; glycoproteins; neutralizing antibody; congenital CMV; pentamer complex; gB; epithelial cells; virus tropism; disabled infectious single cycle (DISC); n/a